Comparative Pharmacology
Head-to-head clinical analysis: LEXXEL versus TRIVARIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEXXEL versus TRIVARIS.
LEXXEL vs TRIVARIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LEXXEL is a combination of felodipine, a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle and cardiac muscle, causing vasodilation and reduced myocardial contractility, and enalapril, an angiotensin-converting enzyme (ACE) inhibitor that prevents conversion of angiotensin I to angiotensin II, reducing vasoconstriction, aldosterone secretion, and sodium reabsorption.
TRIVARIS combines an opioid agonist-antagonist (buprenorphine) and a mu-opioid receptor antagonist (naloxone). Buprenorphine partially binds to mu-opioid receptors, reducing withdrawal and craving, while naloxone precipitates withdrawal if injected, deterring abuse.
1 tablet (felodipine 5 mg / enalapril 5 mg) orally once daily, may increase to 2 tablets once daily after 2-4 weeks if needed.
TRIVARIS 10 mg orally once daily, with or without food.
None Documented
None Documented
Enalapril: ~1.3 hours; Enalaprilat: terminal half-life ~35-38 hours, with multiple-dose accumulation half-life ~11 hours; effective half-life for ACE inhibition ~24 hours.
Terminal half-life 12-18 hours; allows twice-daily dosing in chronic therapy
Renal: ~35-50% as unchanged drug (enalaprilat), biliary/fecal: ~15-30% as metabolites and unchanged drug; total renal elimination of enalaprilat accounts for ~60-80% of dose.
Renal: 60% unchanged; Biliary/Fecal: 30% as metabolites; 10% minor pathways
Category C
Category C
ACE Inhibitor + Calcium Channel Blocker
Angiotensin II Receptor Blocker + Calcium Channel Blocker + Thiazide Diuretic Combination